This is the only study to our knowledge to combine a PARP inhibitor with RT for oesophageal cancer and we have shown that it is feasible to treat patients with olaparib in combination with radical RT and that an olaparib dose of 50 mg twice daily may be tolerable whereas 100 mg twice daily was not. This evidence concerns the gene PARP1 and carcinoma of esophagus.